![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: The aim of this study was to determine whether the functional chemokine receptor 5 delta32 (CCR5-Δ32) polymorphism is associated with multiple sclerosis (MS) susceptibility.
Methods: Meta-analysis was conducted to determine the association between the CCR5-Δ32 polymorphism and overall incidence of MS as well frequency of relapsing-remitting (RR), primary progressive (PP), and secondary progressive (SP) MS subtypes.
Results: In total, 3869 subjects from eight studies (MS 1666, controls 2203) were considered for meta-analysis. Meta-analysis showed no association between MS and the CCR5-Δ32 allele polymorphism (OR = 1.102, 95% CI = 0.830–1.462, p = 0.502) with a mean frequency of 11.3% in MS patients and 10.4% in controls. Stratification by ethnicity indicated no association between the CCR5-Δ32 allele and MS in Europeans (OR = 0.958, 95% CI = 0.811–1.132, p = 0.618). Meta-analysis by the disease subtype showed no association between RR-MS and the CCR5-Δ32 allele (OR = 1.234, 95% CI = 0.908–1.677, p = 0.178). In addition, no association was found between the CCR5-Δ32 polymorphism and PP or SP-MS.
Conclusions: Meta-analysis of 3869 subjects indicates a lack of association between the CCR5-Δ32 polymorphism and MS risk in Europeans.